Growth and Neurodevelopment in Extremely Low-Birth-Weight Neonates Exposed to Postnatal Steroid Therapy

ABSTRACT

We compared postnatal growth and neurodevelopment in extremely low-birth-weight (<1000 g) neonates who did or did not receive postnatal steroid (PNS) therapy for bronchopulmonary dysplasia (BPD). One hundred seventy-three neonates with Bayley Scales of Infant Development II (BSID II) testing performed at 18- to 22-month adjusted age were studied. Growth parameters and BSID II scales were compared among three groups: group I, no BPD; group II, BPD, no PNS; group III, BPD and PNS exposure. A subset of 77 neonates' growth parameters were retrieved at 12-month adjusted age. Psychomotor Development Index (PDI) and Mental Development Index (MDI) scales were lower in group III versus groups I and II. Growth velocity (GV) was lower in group III versus group I and II during the initial hospital stay. In the subset, GV from birth to 1-year adjusted age and weight, length, and head circumference determined at 1-year adjusted age were similar among the groups. Multivariate analysis revealed a significant effect of group membership and cystic periventricular leukomalacia on PDI. These results suggest that a deleterious effect of PNS therapy on neurodevelopment can occur by a mechanism that does not impair overall growth or growth of head circumference.

KEYWORDS

Neonate - preterm - dexamethasone - bronchopulmonary dysplasia - chronic lung disease - neurodevelopment

REFERENCES

• 1 Halliday H L. Clinical trials of postnatal corticosteroids: inhaled and systemic.  Biol Neonate. 1999;  76 (Suppl 1) 29-40
• 2 Doyle L W, Davis P G, Morley C J, McPhee A, Carlin J B. DART Study Investigators . Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial.  Pediatrics. 2006;  117 75-83
• 3 Finer N N, Craft A, Vaucher Y E, Clark R H, Sola A. Postnatal steroids: short-term gain, long-term pain?.  J Pediatr. 2000;  137 9-13
• 4 Tarnow-Mordi W, Mitra A. Postnatal dexamethasone in preterm infants is potentially lifesaving, but follow up studies are urgently needed.  BMJ. 1999;  319 1385-1386
• 5 Barrington K J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs.  BMC Pediatr. 2001;  1 1
• 6 Leib S L, Heimgartner C, Bifrare Y D, Loeffler J M, Täauber M G. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats.  Pediatr Res. 2003;  54 353-357
• 7 LeFlore J L, Salhab W A, Broyles R S, Engle W D. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates.  Pediatrics. 2002;  110 (2 Pt 1) 275-279
• 8 Shinwell E S, Karplus M, Reich D et al.. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F177-F181
• 9 Baud O. Postnatal steroid treatment and brain development.  Arch Dis Child Fetal Neonatal Ed. 2004;  89 F96-F100
• 10 Doyle L W, Halliday H L, Ehrenkranz R A, Davis P G, Sinclair J C. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease.  Pediatrics. 2005;  115 655-661
• 11 Watterberg K L. American Academy of Pediatrics. Committee on Fetus and Newborn . Policy statement—postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia.  Pediatrics. 2010;  126 800-808
• 12 Skidmore M D, Rivers A, Hack M. Increased risk of cerebral palsy among very low-birthweight infants with chronic lung disease.  Dev Med Child Neurol. 1990;  32 325-332
• 13 Vohr B R, Wright L L, Dusick A M et al.. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994.  Pediatrics. 2000;  105 1216-1226
• 14 Papile L A, Tyson J E, Stoll B J et al.. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants.  N Engl J Med. 1998;  338 1112-1118
• 15 Thorp J A, Jones P G, Peabody J L, Knox E, Clark R H. Effect of antenatal and postnatal corticosteroid therapy on weight gain and head circumference growth in the nursery.  Obstet Gynecol. 2002;  99 109-115
• 16 Ehrenkranz R A, Younes N, Lemons J A et al.. Longitudinal growth of hospitalized very low birth weight infants.  Pediatrics. 1999;  104 (2 Pt 1) 280-289
• 17 Tyson J E, Kennedy K, Broyles S, Rosenfeld C R. The small for gestational age infant: accelerated or delayed pulmonary maturation? Increased or decreased survival?.  Pediatrics. 1995;  95 534-538
• 18 Papile L A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm.  J Pediatr. 1978;  92 529-534
• 19 Patel A L, Engstrom J L, Meier P P, Kimura R E. Accuracy of methods for calculating postnatal growth velocity for extremely low birth weight infants.  Pediatrics. 2005;  116 1466-1473
• 20 Halliday H L, Ehrenkranz R A, Doyle L W. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2010;  (1) CD001146
• 21 Halliday H L, Ehrenkranz R A, Doyle L W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2009;  (1) CD001145
• 22 Onland W, Offringa M, De Jaegere A P, van Kaam A H. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials.  Pediatrics. 2009;  123 367-377
• 23 Murphy B P, Inder T E, Huppi P S et al.. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease.  Pediatrics. 2001;  107 217-221
• 24 O'Shea T M, Kothadia J M, Klinepeter K L et al.. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.  Pediatrics. 1999;  104 (1 Pt 1) 15-21
• 25 Yeh T F, Lin Y J, Huang C C et al.. Early dexamethasone therapy in preterm infants: a follow-up study.  Pediatrics. 1998;  101 E7
• 26 Whitelaw A, Thoresen M. Antenatal steroids and the developing brain.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F154-F157
• 27 Jobe A H, Newnham J, Willet K, Sly P, Ikegami M. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids.  Pediatrics. 1998;  102 1116-1125
• 28 Jobe A H, Wada N, Berry L M, Ikegami M, Ervin M G. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep.  Am J Obstet Gynecol. 1998;  178 880-885
• 29 Huang W L, Beazley L D, Quinlivan J A, Evans S F, Newnham J P, Dunlop S A. Effect of corticosteroids on brain growth in fetal sheep.  Obstet Gynecol. 1999;  94 213-218
• 30 Wagerle L C, DeGiulio P A, Mishra O P, Delivoria-Papadopoulos M. Effect of dexamethasone on cerebral prostanoid formation and pial arteriolar reactivity to CO2 in newborn pigs.  Am J Physiol. 1991;  260 (4 Pt 2) H1313-H1318
• 31 Van Marter L J, Kuban K CK, Allred E et al.. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?.  Arch Dis Child Fetal Neonatal Ed. 2011;  96 F20-F29
• 32 Armstrong D L, Bagnall C, Harding J E, Teele R L. Measurement of the subarachnoid space by ultrasound in preterm infants.  Arch Dis Child Fetal Neonatal Ed. 2002;  86 F124-F126
• 33 Radmacher P G, Rafail S T, Adamkin D H. Nutrition and growth in VVLBW infants with and without bronchopulmonary dysplasia.  Neonatal Intensive Care. 2004;  16 22-26
• 34 deRegnier R A, Guilbert T W, Mills M M, Georgieff M K. Growth failure and altered body composition are established by one month of age in infants with bronchopulmonary dysplasia.  J Nutr. 1996;  126 168-175
• 35 Weiler H A, Paes B, Shah J K, Atkinson S A. Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone.  Early Hum Dev. 1997;  47 271-286
• 36 Armstrong D L, Penrice J, Bloomfield F H, Knight D B, Dezoete J A, Harding J E. Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease.  Arch Dis Child Fetal Neonatal Ed. 2002;  86 F102-F107
• 37 Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up.  Pediatrics. 1995;  96 (5 Pt 1) 897-906